Elite Pharmaceuticals, Inc. (ELTP)
| Market Cap | 56.51M |
| Revenue (ttm) | 25.93M |
| Net Income (ttm) | 6.51M |
| Shares Out | 1.01B |
| EPS (ttm) | 0.01 |
| PE Ratio | 7.47 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 15 |
| Last Price | $0.0523 |
| Previous Close | $0.0566 |
| Change ($) | -0.0043 |
| Change (%) | -7.60% |
| Day's Open | 0.0532 |
| Day's Range | 0.0523 - 0.0569 |
| Day's Volume | 204,470 |
| 52-Week Range | 0.0480 - 0.0995 |
News
NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products...
About ELTP
Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets fo... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jul 23, 1998 |
| Stock Exchange OTCMKTS | Ticker Symbol ELTP |
Financial Performance
In 2019, ELTP's revenue was $17.99 million, an increase of 137.76% compared to the previous year's $7.57 million. Losses were -$2.24 million, -75.86% less than in 2018.